The longterm outcomes of macular neovascularization treated with intravitreal injections of anti-VEGF drugs

The longterm outcomes of macular neovascularization treated with intravitreal injections of anti-VEGF drugs - AMD treated by anti-VEGF drugs

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033408

Enrollment

300

Registered

2018-07-17

Start date

2016-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AMD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent intravitreal injection to Aflbercept or Ranibizumab for age-related macular degeneration from March 1, 2016 to December 31, 2020

Exclusion criteria

Exclusion criteria: nothing special

Design outcomes

Primary

Measure	Time frame
Sex, age, visual acuity, visual field, refraction, corneal curvature radius, corneal thickness, ocular axial length, fundus observation,Optical coherence tomography, optical coherence tomography angiography, fundus photograph, fluorescence fundus angiography, slit lamp microscopy, duration of disease, current medical history, past history, family history, medication used, frequency of dosing	—

Countries

Japan

Contacts

Public ContactKeiko Kataoka

Nagoya University Hospital Department of Ophthalmology

kkeiko@med.nagoya-u.ac.jp052-744-2275

Outcome results